ArticleBiochemistry2012
X-aptamers: a bead-based selection method for random incorporation of druglike moieties onto next-generation aptamers for enhanced binding.
Article in Biochemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 69 citations in OpenAlex.
- Aptamer Engineering: Strategies for Discovering Functional Nucleic Acids for Next-Generation Diagnostics and Biosensing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Development and Characterization of CD44-Targeted X-Aptamers with Enhanced Binding Affinity for Cancer Therapeutics.Bioengineering (Basel, Switzerland) · 2025Article
- Aptamer based immunotherapy: a potential solid tumor therapeutic.Frontiers in immunology · 2025Review
- A Non-G-Quadruplex DNA Aptamer Targeting NCL for Diagnosis and Therapy in Bladder Cancer.Advanced healthcare materials · 2023Article
- Targeting extracellular CIRP with an X-aptamer shows therapeutic potential in acute pancreatitis.iScience · 2023Article
- Aptamers based sensing of pregnancy associated glycoproteins (PAG) of bovine for early pregnancy detection.Scientific reports · 2021Article
- Neutralizing Aptamers Block S/RBD-ACE2 Interactions and Prevent Host Cell Infection.Angewandte Chemie (Weinheim an der Bergstrasse, Germany) · 2021Article
- Neutralizing Aptamers Block S/RBD-ACE2 Interactions and Prevent Host Cell Infection.Angewandte Chemie (International ed. in English) · 2021Article
- Recent Progress and Opportunities for Nucleic Acid Aptamers.Life (Basel, Switzerland) · 2021Review
- X-aptamers targeting Thy-1 membrane glycoprotein in pancreatic ductal adenocarcinoma.Biochimie · 2021Article
- Aptamers against Immunoglobulins: Design, Selection and Bioanalytical Applications.International journal of molecular sciences · 2020Review
- Diagnostic and Therapeutic Value of Aptamers in Envenomation Cases.International journal of molecular sciences · 2020Review
- Ligand-Guided Selection with Artificially Expanded Genetic Information Systems against TCR-CD3ε.Biochemistry · 2020Article
- Aptamers Chemistry: Chemical Modifications and Conjugation Strategies.Molecules (Basel, Switzerland) · 2019Review
- Perspective on the Future Role of Aptamers in Analytical Chemistry.Analytical chemistry · 2019Article
- X-Aptamer Technology Identifies C4A and ApoB in Blood as Potential Markers for Schizophrenia.Molecular neuropsychiatry · 2019Article
- Discovery of Novel Bovine Viral Diarrhea Inhibitors Using Structure-Based Virtual Screening on the Envelope Protein E2.Frontiers in chemistry · 2018Article
- Simple Methods and Rational Design for Enhancing Aptamer Sensitivity and Specificity.Frontiers in molecular biosciences · 2018Article
- Nonantimicrobial drug targets for Clostridium difficile infections.Future microbiology · 2017Article
- Engineered Aptamers to Probe Molecular Interactions on the Cell Surface.Biomedicines · 2017Review
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 5 institutions in 4 countries.
Funding
Abstract
By combining pseudorandom bead-based aptamer libraries with conjugation chemistry, we have created next-generation aptamers, X-aptamers (XAs). Several X-ligands can be added in a directed or random fashion to the aptamers to further enhance their binding affinities for the target proteins. Here we describe the addition of a drug (N-acetyl-2,3-dehydro-2-deoxyneuraminic acid), demonstrated to bind to CD44-HABD, to a complete monothioate backbone-substituted aptamer to increase its binding affinity for the target protein by up to 23-fold, while increasing the drug's level of binding 1-million fold.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.